体外右心室辅助装置联合持久左心室辅助装置支持后的结局
该研究基于杜克大学医学中心2007年10月至2017年10月的数据,分析了43例连续接受持久左心室辅助装置(LVAD)并同期或分期(7天内)植入体外临时右心室辅助装置(RVAD)的成人患者。结果显示,67%的患者可撤除RVAD转为单独LVAD,30天、住院期间和总死亡率分别为14%、28%和51%;分期RVAD组总死亡率71%高于同期组45%(p=0.101),且术后肾衰竭发生率显著更高(64% vs 28%,p=0.044)。结论认为早期RVAD支持与较低肾衰竭率相关,但双心室支持的并发症和死亡率仍较高。
要点
- LVAD植入后需RVAD支持者比例低,多数可撤除RVAD转为单独LVAD。
- 分期RVAD组术后肾衰竭发生率显著高于同期RVAD组(64% vs 28%,p=0.044)。
- 双心室支持的并发症和死亡率仍较高,需谨慎管理。
核心结论
- 本队列中需要RVAD的发生率低,多数患者可撤除RVAD转为单独LVAD。
- 这种双心室支持的并发症和死亡率仍较高。
- 早期建立RVAD支持与较低的LVAD术后肾衰竭率相关。
研究设计与样本
- 回顾性队列研究,数据来自杜克大学医学中心数据库。
- 纳入2007年10月至2017年10月所有连续接受持久LVAD并同期或分期(7天内)植入体外临时RVAD的成人患者。
- 共43例患者,其中同期植入29例(67%),分期植入14例(33%)。
主要发现
- 43例中67%(n=29)可撤除RVAD转为单独LVAD。
- 30天死亡率为14%,住院期间死亡率为28%,总死亡率为51%。
- 分期植入组总死亡率为71%,同期植入组为45%(p=0.101)。
- 分期RVAD组术后肾衰竭发生率显著高于同期组(64% vs 28%,p=0.044)。
临床怎么用
- 对于LVAD术后需RVAD支持的患者,应考虑早期建立RVAD以降低肾衰竭风险。
- 分期RVAD植入者需警惕较高的肾衰竭和死亡风险,加强术后监测。
局限性
- 回顾性单中心研究,样本量较小(43例)。
- 分期与同期组间死亡率差异未达统计学显著性(p=0.101),可能受样本量限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Right heart failure occurs in 9% to 44% of left ventricular assist device (LVAD) implants, of which less than 10% require right ventricular assist device (RVAD) support either concurrently with the LVAD or staged, as a delayed procedure. We have reported our outcomes based on whether the RVAD was placed concurrently or staged. METHODS: Clinical data were obtained from the Duke University Medical Center database. The study focused on all consecutive adult patients who received continuous flow LVAD with either concurrent or staged (within 7 days) extracorporeal, temporary RVAD, between October 2007 and October 2017. Adverse event profiles and ability to wean from RVAD were compared between these two groups. RESULTS: Overall, 43 patients required an extracorporeal RVAD; 67% (n = 29) were implanted concurrently and 33% (n = 14) were implanted as staged after the LVAD. In all, 67% of patients (n = 29) could be weaned to an isolated LVAD. The 30-day, inhospital, and total mortality rates for our cohort were 14%, 28%, and 51% respectively. The mortality rate in the study period for the staged implants was 71% versus 45% for the concurrent implants (p = 0.101). In addition, staged RVAD implantation carried a significantly higher rate of postoperative renal failure (64% versus 28%, p = 0.044). CONCLUSIONS: There was a low incidence of need for RVAD in our cohort. The majority could be weaned to an isolated LVAD. Morbidity and mortality rates of this mode of biventricular support remain high. Early institution of RVAD support was associated with reduced rates of post-LVAD renal failure rates.
引用
- Khorsandi M, Schroder J, Daneshmand M, et al. Outcomes After Extracorporeal Right Ventricular Assist Device Combined With Durable Left Ventricular Assist Device Support. Ann Thorac Surg. 2018. PMID: 30582926. doi:10.1016/j.athoracsur.2018.11.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。